분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-12-12 11:30:57 , Hit : 1142
 FDA approves 9-valent HPV vaccine for certain cancers

FDA approvals
  
December 10, 2014
  

The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of anal, cervical, vaginal and vulvar cancers.

  

See Also
HPV vaccination rates among girls lowest in states with ...
Few physicians routinely recommend HPV vaccine to boys ...
Effective implementation of nine-valent HPV vaccination could ...
  

The recombinant HPV 9-valent vaccine (Gardasil 9, Merck) covers nine HPV types, which is five more than the quadrivalent HPV vaccine (Gardasil).

The vaccine is indicated for females aged 9 to 26 years and males aged 9 to 15 years, and for cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58 and for the prevention of genital warts caused by HPV types 6 or 11.

The additional five types of HPV that Gardasil 9 adds protection against (31, 33, 45, 52 and 58) are the cause of approximately 20% of cervical cancers and are not covered in previous FDA-approved HPV vaccines.

“Vaccination is a critical public health measure for lowering the risk of most cervical, genital and anal cancers caused by HPV,” Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release. “The approval of Gardasil 9 provides broader protection against HPV-related cancers.”

Karen Midthun, MD
Karen Midthun

A randomized controlled international study was conducted using a cohort of approximately 14,000 females (median age, 21 years) who tested negative for vaccine HPV types at the start of the study. Patients were randomly assigned Gardasil 9 or Gardasil.

Gardasil 9 was found to be 97% effective in preventing cervical, vulvar and vaginal cancers caused by the additional HPV types.

In addition, Gardasil 9 was equally as effective as Gardasil in the prevention in the four other HPV types (6, 11, 16 and 18).

There is a low incidence of anal cancer caused by the five additional HPV types. As such, the preventive analysis is based on Gardasil’s demonstrated effectiveness of 78% and additional data on antibodies in males and females who received Gardasil 9.

For children aged 9 to 15 years, the effectiveness of Gardasil 9 was identified in studies that measured antibody response to the vaccine. The study group consisted of approximately 1,200 males and 2,800 females. Their response was similar to participants aged 16 to 26 years. Therefore, the vaccine is expected to have similar effectiveness in the younger age group.

Gardasil 9 is administered as three separate vaccinations, with the initial dose followed by additional vaccinations 2 to 6 months later.

Indications are that patients vaccinated before becoming infected with the HPV strains would benefit the most from Gardasil 9.

The safety of the agent was evaluated in approximately 13,000 males and females, and the most common adverse effects were pain at the injection site, swelling, redness and headaches.







1107   Dynamic view of the MS genome  이성욱 2010/05/01 2718
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2516
1105   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 821
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2239
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3166
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1284
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2337
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 782
1099   Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2445
1098   Engineering Better Immune Cells  이성욱 2010/05/06 2700
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1147
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2669
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 780
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 401
1093   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2135
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2571
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 799
  FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
1089   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 512
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 609

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN